Cargando…

Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment

Cancer incidence appears to be increased in both type 1 and type 2 diabetes mellitus (DM). DM represents a risk factor for cancer, particularly hepatocellular, hepatobiliary, pancreas, breast, ovarian, endometrial, and gastrointestinal cancers. In addition, there is evidence showing that DM is assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Suh, Sunghwan, Kim, Kwang-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Diabetes Association 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943263/
https://www.ncbi.nlm.nih.gov/pubmed/31902143
http://dx.doi.org/10.4093/dmj.2019.0177
_version_ 1783484852476051456
author Suh, Sunghwan
Kim, Kwang-Won
author_facet Suh, Sunghwan
Kim, Kwang-Won
author_sort Suh, Sunghwan
collection PubMed
description Cancer incidence appears to be increased in both type 1 and type 2 diabetes mellitus (DM). DM represents a risk factor for cancer, particularly hepatocellular, hepatobiliary, pancreas, breast, ovarian, endometrial, and gastrointestinal cancers. In addition, there is evidence showing that DM is associated with increased cancer mortality. Common risk factors such as age, obesity, physical inactivity and smoking may contribute to increased cancer risk in patients with DM. Although the mechanistic process that may link diabetes to cancer is not completely understood yet, biological mechanisms linking DM and cancer are hyperglycemia, hyperinsulinemia, increased bioactivity of insulin-like growth factor 1, oxidative stress, dysregulations of sex hormones, and chronic inflammation. However, cancer screening rate is significantly lower in people with DM than that in people without diabetes. Evidence from previous studies suggests that some medications used to treat DM are associated with either increased or reduced risk of cancer. However, there is no strong evidence supporting the association between the use of anti-hyperglycemic medication and specific cancer. In conclusion, all patients with DM should be undergo recommended age- and sex appropriate cancer screenings to promote primary prevention and early detection. Furthermore, cancer should be screened in routine diabetes assessment.
format Online
Article
Text
id pubmed-6943263
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Korean Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-69432632020-01-09 Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment Suh, Sunghwan Kim, Kwang-Won Diabetes Metab J Review Cancer incidence appears to be increased in both type 1 and type 2 diabetes mellitus (DM). DM represents a risk factor for cancer, particularly hepatocellular, hepatobiliary, pancreas, breast, ovarian, endometrial, and gastrointestinal cancers. In addition, there is evidence showing that DM is associated with increased cancer mortality. Common risk factors such as age, obesity, physical inactivity and smoking may contribute to increased cancer risk in patients with DM. Although the mechanistic process that may link diabetes to cancer is not completely understood yet, biological mechanisms linking DM and cancer are hyperglycemia, hyperinsulinemia, increased bioactivity of insulin-like growth factor 1, oxidative stress, dysregulations of sex hormones, and chronic inflammation. However, cancer screening rate is significantly lower in people with DM than that in people without diabetes. Evidence from previous studies suggests that some medications used to treat DM are associated with either increased or reduced risk of cancer. However, there is no strong evidence supporting the association between the use of anti-hyperglycemic medication and specific cancer. In conclusion, all patients with DM should be undergo recommended age- and sex appropriate cancer screenings to promote primary prevention and early detection. Furthermore, cancer should be screened in routine diabetes assessment. Korean Diabetes Association 2019-12 2019-12-23 /pmc/articles/PMC6943263/ /pubmed/31902143 http://dx.doi.org/10.4093/dmj.2019.0177 Text en Copyright © 2019 Korean Diabetes Association http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Suh, Sunghwan
Kim, Kwang-Won
Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
title Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
title_full Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
title_fullStr Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
title_full_unstemmed Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
title_short Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
title_sort diabetes and cancer: cancer should be screened in routine diabetes assessment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943263/
https://www.ncbi.nlm.nih.gov/pubmed/31902143
http://dx.doi.org/10.4093/dmj.2019.0177
work_keys_str_mv AT suhsunghwan diabetesandcancercancershouldbescreenedinroutinediabetesassessment
AT kimkwangwon diabetesandcancercancershouldbescreenedinroutinediabetesassessment